CROS NT’s biostatistics team has a range of experience, from the planning and design of a trial, to reporting and regulatory submission guidance.

It is generally agreed that the best time to involve a biostatistician in a clinical study is at its inception. This allows the biostatistician to support with common biostatistics challenges in clinical research: understanding the study design and making suggestions on hypothesis testing and analysis.

CROS NT has performed statistical analysis and reporting activities for thousands of studies in a variety of therapeutic areas, in all phases of drug development and medical device trials.

Our biostatisticians deliver the following services:

Planning

  • Study Design and complex study design including Adaptive and Bayesian
  • Power/sample size calculations
  • Protocol Writing and Review
  • CRF Design & Review
  • Statistical Analysis Plan

Analysis

  • Production and Validation of Interim Analysis and Reports
  • Meta-Analysis
  • Ad hoc analyses
  • Preparation of Integrated Summaries of Safety & Efficacy

Reporting

  • Filing and Reporting with Regulatory Bodies (FDA and EMA)
  • Statistical Analysis Reports including the statistical analysis part of the Clinical Study Report
  • Centralized Statistical Intelligence to facilitate Risk-Based Monitoring

Adaptive Trial Design in Biostatistics

CROS NT’s biostatistics team has particular expertise in Adaptive Trial Design: a flexible methodology in which modifications are made along the way based on the analysis of collected data in order to reduce timelines and costs.

Our statisticians have applied this methodology to many studies in various therapeutic areas to change treatment allocation ratios, reassess sample size, modify the hypothesis or drop/add treatment arms. We have particular expertise in oncology studies which carry unique characteristics that can benefit from adaptive trial design.